SP 0269
Alternative Names: Chlamydia trachomatis vaccine - Sanofi; SP-0269Latest Information Update: 01 Jul 2025
At a glance
- Originator Sanofi
- Class Antibacterials; RNA
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Chlamydial infections
Most Recent Events
- 26 Mar 2025 SP 0256 receives fast track Fast Track designation for Chlamydial infections (Prevention) in USA
- 25 Mar 2025 Phase-I/II clinical trials in Chlamydial infections in Australia (IM)
- 01 Mar 2025 Sanofi plans phase I/II in Chlamydial infections (Prevention, In adolescents and In elderly) (IM, Injection) (NCT06891417)